Chordoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Conditions: Effect of Drugs; Quality of Life; Chordoma; Advanced Cancer Intervention: Drug: Anlotinib Hydrochloride Sponsors: Peking University People's Hospital; Peking University Shougang Hospital; Peking University Third Hospital; Peking University First Hospital; Beijing Jishuitan Hospital; Chinese PLA General Hospital; Beijing Cancer Hospital; Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2019 Category: Research Source Type: clinical trials

Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma: a Multicentre, Open-label, Randomised Phase 2 Trial
Conditions: Effect of Drugs; Quality of Life; Chordoma; Advanced Cancer Intervention: Drug: Anlotinib Hydrochloride Sponsors: Peking University People's Hospital; Peking University Shougang Hospital; Peking University Third Hospital; 3Peking University First Hospital; Beijing Jishuitan Hospital; People's Liberation Army General Hospital (301); Beijing Cancer Hospital; Cancer In stitute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2019 Category: Research Source Type: clinical trials